Tempest Therapeutics
TPST
38 hedge funds and large institutions have $90.7M invested in Tempest Therapeutics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 8 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
27% more funds holding
Funds holding: 30 → 38 (+8)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less capital invested
Capital invested by funds: $104M → $90.7M (-$13.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.68M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.92M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.76M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$1.75M |
| 5 |
Renaissance Technologies
New York
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$2.97M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$756K |
| 3 |
Millennium Management
New York
|
-$749K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$303K |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$276K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$2K | -1 | Closed |
|
TPST Hedge Fund Activity: Q2 2019 in Review
38 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2019, worth a combined $90.7M — down 13% from $104M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TPST positions and 8 closed out — a net gain of 8 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $6.68M. The largest seller was Prosight Management, cutting an estimated $2.97M.
- 38 institutional investors held Tempest Therapeutics (TPST) as of Q2 2019, up from 30 in Q1 2019.
- Funds reported $90.7M of Tempest Therapeutics stock for Q2 2019, down 13% quarter-over-quarter.
- 16 funds opened new Tempest Therapeutics positions in Q2 2019 and 8 closed out, a net change of +8 holders.
- The largest Tempest Therapeutics buyer in Q2 2019 was BlackRock, an estimated $6.68M added.
- The largest Tempest Therapeutics seller in Q2 2019 was Prosight Management, an estimated $2.97M sold.
Based on aggregated 13F filings for Q2 2019.